AMRI (AMRI) Misses Q4 EPS by 1c; Guides Q111, FY11 Revs Below Street
Tweet Send to a FriendGet Alerts AMRI Hot Sheet
Price: $11.76 -1.75%
EPS Growth %: +1,050.0%
Financial Fact:
Cost of contract revenue: 37.82M
Today's EPS Names:
CEDU, CHC, CIDM, More
EPS Growth %: +1,050.0%
Financial Fact:
Cost of contract revenue: 37.82M
Today's EPS Names:
CEDU, CHC, CIDM, More
Trade AMRI Now!
Albany Molecular Research Inc. (NASDAQ: AMRI) reported Q4 loss of $0.16, 1 cent worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $48.6 million versus the consensus estimate of $47.87 million.
AMRI seess Q111 revenue of $37 - $41 million, versus the consensus of $57.38 million.
AMRI sees FY11 revenue of $179 - $187 million, versus the consensus of $216.50 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
AMRI seess Q111 revenue of $37 - $41 million, versus the consensus of $57.38 million.
AMRI sees FY11 revenue of $179 - $187 million, versus the consensus of $216.50 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jabil Circuit (JBL) Tops Q3 EPS by 2c; Issues Light Q4 Outlook; Will Realign Global Ops
- AMRI Burlington Receives DEA Approval to Handle Controlled Substances
- Finisar Corp (FNSR) Tops Q4 EPS by 3c; Guides Q1 EPS Above Views
Create E-mail Alert Related Categories
Earnings, Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
